

## DAFTAR PUSTAKA

- Abdel-Rahman, O. (2019). Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials. *Clinical Colorectal Cancer*, 18(4), e385–e393. <https://doi.org/10.1016/j.clcc.2019.07.005>
- Abu-Rustum, N., Yashar, C., Bean, S., Bradley, K., Chon, H., Cohn, D., ... Damast, S. (2019). Cervical Cancer. *NCCN Clinical Practice Guidelines in Oncology*. Retrieved from <https://www2.tri-kobe.org/nccn/guideline/gynecological/english/cervical.pdf>
- Aldossary, S. A. (2019). Review on Pharmacology of Cisplatin : Clinical Use , Toxicity and Mechanism of Resistance of Cisplatin. *Biomedical & Pharmacology Journal*, 12(March), 7–15. <http://dx.doi.org/10.13005/bpj/1608>
- Arbyn, M., Weiderpass, E., Bruni, L., Sanjosé, S. De, Saraiya, M., Ferlay, J., ... Foundation, M. G. (2019). Articles Estimates of Incidence and Mortality of Cervical Cancer in 2018 : a Worldwide Analysis. *Lancet*, (19), 1–13. [https://doi.org/10.1016/S2214-109X\(19\)30482-6](https://doi.org/10.1016/S2214-109X(19)30482-6)
- Bagri, P., Kapoor, A., Kalwar, A., Singhal, M., Singh, D., & Narayan, S. (2014). Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy. *South Asian Journal of Cancer*, 3(4). <https://doi.org/10.4103/2278-330X.142979>
- Department
- Baskar, R., Dai, J., Wenlong, N., Yeo, R., Yeoh, K., & Rogers, B. (2014). Biological Response of Cancer Cells to Radiation Treatment, 1(November), 1–9. <https://doi.org/10.3389/fmolb.2014.00024>
- Bhatla, N., Aoki, D., Sharma, D., & Sankaranarayanan, S. (2018). FIGO Cancer Report 2018. *Int J Gynecol Obstet*, 143. <https://doi.org/10.1002/ijgo.12611>
- FIGO
- Bhatla, N., Berek, J. S., Cuello, M., Lynette, F., Grenman, S., Karunaratne, K., ...

- Sankaranarayanan, R. (2019). Revised FIGO Staging for Carcinoma of the Cervix Uteri. *Int J Gynecol Obstet*, 143(July 2018), 129–135. <https://doi.org/10.1002/ijgo.12749>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L., & Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Ca Cancer J Clin*, 394–424. <https://doi.org/10.3322/caac.21492>
- Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013). Power failure: Why small sample size undermines the reliability of neuroscience. *Nature Reviews Neuroscience*, 14(5), 365–376. <https://doi.org/10.1038/nrn3475>
- Caradonna, S. (2011). *Encyclopedia of Cancer*. <https://doi.org/10.1007/978-3-642-16483-5>
- Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019). Seminar Cervical cancer. *Lancet*, 393(10167), 169–182. [https://doi.org/10.1016/S0140-6736\(18\)32470-X](https://doi.org/10.1016/S0140-6736(18)32470-X)
- DeVita, H., Lawrence, T., & Rosenberg, S. (2019). *Cancer Principles & Practice of Oncology 11th Edition* (11th ed.). United States of America Library: Wolters Kluwer.
- Edmonds, D., Less, C., & Bourne, T. (2018). *Dewhurst 's Textbook of Obstetrics & Gynaecology*. (F. D. Keith Edmonds MB, ChB, FRCOG, Ed.) (First Edit). USA.
- Eifel, P. J., Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., ... Mutch, D. G. (2004). Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial ( RTOG ) 90-01. *Journal of Clinical Oncology*, 22(5). <https://doi.org/10.1200/JCO.2004.07.197>
- Falcetta, F., Medeiros, L., Edelweiss, M., Pohlmann, P., Stein, A., & Rosa, D. (2016). Adjuvant Platinum-Based Chemotherapy for Early Stage Cervical Cancer ( Review ). *Cochrane Database of Systematic Reviews*, (11).

<https://doi.org/10.1002/14651858.CD005342.pub4>.[www.cochranelibrary.com](http://www.cochranelibrary.com)

m

- Fata, F., Mirza, A., CraigWood, G., Nair, S., Law, A., Gallagher, J., ... Bernath, A. (2002). Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: A 10-year experience of the Geisinger Medical Center. *Cancer*, 94(7), 1931–1938. <https://doi.org/10.1002/cncr.10430>
- Fu, Z., Li, K., Peng, Y., Zheng, Y., Cao, L., Zhang, Y., & Sun, Y. (2017). Efficacy and Toxicity of Different Concurrent Chemoradiotherapy Regimens in The Treatment of Advanced Cervical Cancer. *Medicine*, 0(April 2016). <https://doi.org/http://dx.doi.org/10.1097/MD.00000000000005853>
- Gutierrez, F., Gonzalez-de-la-Fuente, G. A., Nazco, G. J., Oramas, J., & Batista, N. (2016). Hematological toxicity of carboplatin for gynecological cancer according to body mass index. *European Journal of Clinical Pharmacology*, 72(9), 1083–1089. <https://doi.org/10.1007/s00228-016-2080-7>
- Hoffman, B., Schorge, J., Bradshaw, K., Halvorson, L., Schaffer, J., & Corton, M. (2016). *Williams Gynecology* (Third Edit). USA.
- HOGI. (2018). Pedomana Nasional Pelayanan Kedokteran Kanker Serviks.
- ICO/IARC Information Centre on HPV and Cancer. (2019). Human Papillomavirus and Related Diseases Report, (June). Retrieved from [www.hpvcentre.net](http://www.hpvcentre.net)
- Ishibashi, M., Ishii, M., Yamamoto, S., & Mori, Y. (2020). Possible involvement of TRPM2 activation in 5-fluorouracil-induced myelosuppression in mice. *European Journal of Pharmacology*, (October), 173671. <https://doi.org/10.1016/j.ejphar.2020.173671>
- Jakubowicz, J., Blecharz, P., Skotnicki, P., Reinfuss, M., Walasek, T., & Luczynska, E. (2014). Toxicity of Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer. *Eur. J. Gynaec. Oncol*, XXXV(4). <https://doi.org/10.12892/ejgo24342014>
- Kim, Y., Shin, S., Nam, J., Kim, Y., Kim, Y., Hoon, J., & Kyung, E. (2008). Prospective Randomized Comparison of Monthly Fluorouracil and Cisplatin versus Weekly Cisplatin Concurrent with Pelvic Radiotherapy and High-

Dose Rate Brachytherapy for Locally Advanced Cervical Cancer.  
*Gynecologic Oncology*, 108, 195–200.  
<https://doi.org/10.1016/j.ygyno.2007.09.022>

Kong, T. W., Chang, S., Paek, J., Yoo, S., Yoon, J., & Chang, K. (2012a). Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. *Journal of Gynecologic Oncology*, 23(4), 235–241.  
<https://doi.org/http://dx.doi.org/10.3802/jgo.2012.23.4.235> pISSN

Kong, T. W., Chang, S., Paek, J., Yoo, S., Yoon, J., & Chang, K. (2012b). Comparison of Concurrent Chemoradiation Therapy with Weekly Cisplatin Versus Monthly Fluorouracil Plus Cisplatin in FIGO Stage IIB-IVA Cervical Cancer. *J Gynecol Oncol*, 23(4), 235–241.  
<https://doi.org/10.3802/jgo.2012.23.4.235>

Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-Fluorouracil : Mechanisms of Action and Clinical Strategies. *Nature*, 3(May), 330–338.  
<https://doi.org/10.1038/nrc1074>

López, J. A., Judith, A., & López, J. G. (2017). MiRNAs in Cervical Cancer Radio- and Chemotherapy Response. <https://doi.org/10.5772/68010>

Ma, S., Wang, J., Han, Y., Guo, F., Chen, C., Chen, X., & Zou, W. (2019). Platinum Single-Agent vs. Platinum-Based Doublet Agent Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: A Meta-Analysis of Randomized Controlled Trials. *Gynecologic Oncology*, 154(1), 246–252. <https://doi.org/10.1016/j.ygyno.2019.04.013>

Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017). Cervical cancer : ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. *Annals of Oncology*, 28(Supplement 4), 72–83. <https://doi.org/10.1093/annonc/mdx220>

Mittal, A., Agarwal, A., Rangaraju, R. R., Batra, S., Gouda D, C., & Qureshi, S. (2018). Can we estimate the risk of chemotherapy toxicity in Indian geriatric patient population and utility of CRASH (chemotherapy risk assessment scale for high age patients) score? *Annals of Oncology*, 29, ix137.

<https://doi.org/10.1093/annonc/mdy444.028>

- Moore, K. N., Frank, S. G., Alward, E. K., Landrum, L. M., Myers, T. K., L. Walker, J., ... Mannel, R. S. (2009). Adjuvant chemotherapy for the “Oldest Old” ovarian cancer patients: Can we anticipate toxicity-related treatment failure in a vulnerable population? *Cancer*, 115(7), 1472–1480. <https://doi.org/10.1002/cncr.24190>
- Murillo, R., Herrero, R., Sierra, M. S., & Forman, D. (2016). Etiology of Cervical Cancer ( C53 ) in Central and South America. Retrieved from [http://www-dep.iarc.fr/CSU\\_resources.htm](http://www-dep.iarc.fr/CSU_resources.htm)
- Nedovic, J., Protrka, Z., Ninkovic, S., Mitrovic, S., Vojinovic, R., Glisic, J., ... Cvetkovic, A. (2012). Cisplatin monotherapy with concurrent radiotherapy versus combination of cis- platin and 5-fluorouracil chemotherapy with concurrent radiotherapy in patients with locoregionally advanced cervical carcinoma. *Journal of BUON*, 740–745. Retrieved from <https://jbuon.com/archive/17-4-740.pdf>
- Peters, W., Liu, P., Barrett, R., Stock, R., Monk, B. J., Berek, J., ... Alberts, D. (2000). Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. *Journal of Clinical Oncology*, 18(8), 1606–1613. <https://doi.org/10.1200/JCO.2000.18.8.1606>
- Petrovic, M., & Danijela, T. (2016). Biochemical and Molecular Mechanisms of Action of Cisplatin in Cancer Cells. *Medicine and Biology*, 18(1), 12–18. Retrieved from <https://core.ac.uk/download/pdf/228557048.pdf>
- Rashid, S., Ali, N., Nafees, S., Hasan, S. K., & Sultana, S. (2014). Mitigation of 5-Fluorouracil induced renal toxicity by chrysin via targeting oxidative stress and apoptosis in wistar rats. *Food and Chemical Toxicology*, 66, 185–193. <https://doi.org/10.1016/j.fct.2014.01.026>
- Sastroasmoro, S., & Ismael, S. (2011). *Dasar-dasar Metodologi Penelitian Klinis* (4th ed.). Jakarta: Sagung Seto.
- Schwab, M. (2011). *Encyclopedia of Cancer* (Vol. 16). Springer-Verlag Berlin Heidelberg. <https://doi.org/10.1007/978-3-642-16483-5>

- Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007). The Concurrent Chemoradiation Paradigm — General Principles. *Nature Clinical Practice Oncology*, 4(2), 86–100. <https://doi.org/10.1038/ncponc0714>
- Sonoda, K., Yahata, H., Ichinoe, A., Okugawa, K., Ohga, S., Asai, K., ... Kato, K. (2015). Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer. *Anticancer Research*, 3454, 3447–3454. Retrieved from <https://ar.iijournals.org/content/anticancer/35/6/3447.full.pdf>
- Tekalegn, Y., Sahiledengle, B., Atlaw, D., Woldeyyohannes, D., Desta, F., Bekele, K., & Assefa, T. (2021). High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. *Research Square*, 1–14. <https://doi.org/https://doi.org/10.21203/rs.3.rs-397999/v1>
- U.S. Department of Health and Human Services. (2017). Common Terminology Criteria for Adverse Events (CTCAE). Retrieved from [https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/ctcae\\_v5\\_quick\\_reference\\_5x7.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)
- Yim, E., Lee, S. B., Lee, K., Kim, C., & Park, J. (2006). Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells. *Int J Gynecol Cancer*, (6), 1321–1329. <https://doi.org/10.1111/j.1525-1438.2006.00551.x>